scholarly journals Hyperuricemia as a Predictive Marker for Progression of Nephrosclerosis: Clinical Assessment of Prognostic Factors in Biopsy-Proven Arterial/Arteriolar Nephrosclerosis

2017 ◽  
Vol 24 (6) ◽  
pp. 630-642 ◽  
Author(s):  
Kumiko Momoki ◽  
Hiroshi Kataoka ◽  
Takahito Moriyama ◽  
Toshio Mochizuki ◽  
Kosaku Nitta
Keyword(s):  
Prognostic Factors ◽  
Clinical Assessment ◽  
Predictive Marker ◽  
Arteriolar Nephrosclerosis

scholarly journals Causes of Raynaud’s phenomenon and the predictive laboratory and capillaroscopy features for the evolution to a definite connective tissue disease

Rheumatology ◽  
2021 ◽  
Author(s):  
Saeedeh Shenavandeh ◽  
Mehrnoush Ajri ◽  
Sahand Hamidi
Keyword(s):  
Risk Factors ◽  
Cohort Study ◽  
Prognostic Factors ◽  
Retrospective Cohort ◽  
Predictive Marker ◽  
Number Of Patients ◽  
Laboratory Results ◽  
Secondary Causes ◽  
Scleroderma Pattern

Abstract Objective In patients with RP, capillaroscopy is useful for discriminating primary from secondary causes. There are certain capillaroscopy and lab values as predictive factors leading to a known CTD. We conducted the present study to evaluate the causes of RP in our area and followed the studied subjects to find prognostic factors indicating a definite CTD or remaining a UCTD. Methods In this retrospective cohort study we included all adult patients with RP who were referred for capillaroscopy from 2010 to 2019. All the patients with primary and secondary RP with follow-up were evaluated for demography, laboratory results and capillaroscopy to find the risk factors of their progression to a CTD. Results A total of 760 of 776 patients were included, with 679 being female (89.3%) and 81 (10.7%) male. There were 660 subjects (90.8%) with secondary RP [mostly UCTD (48.2%) and then SSc (16.4%)] and 67 (9.2%) with primary RP; 109 patients were followed up and 42 (42%) of those with secondary RP developed a definite CTD. The scleroderma pattern and some capillary changes on capillaroscopy and/or positive ANA had statistically significant differences for CTD transition. Conclusion We had a small number of patients with primary RP. The most prevalent causes of secondary RP in our patients were UCTD and SSc. Some capillaroscopy and laboratory results alone or in combination could be used as a predictive marker for the transition of patients with UCTD to CTD.

scholarly journals Prognostic factors for mortality among patients above the 6th decade undergoing non-cardiac surgery: cares - clinical assessment and research in elderly surgical patients

Clinics ◽  
2008 ◽  
Vol 63 (2) ◽  
pp. 151-156 ◽  
Author(s):  
Adriana Nunes Machado ◽  
Maria do Carmo Sitta ◽  
Wilson Jacob Filho ◽  
Luíz Eugênio Garcez-Leme
Keyword(s):  
Cardiac Surgery ◽  
Prognostic Factors ◽  
Clinical Assessment ◽  
Surgical Patients

Clinical assessment of prognostic factors for long-term pain and handicap after whiplash injury: a 1-year prospective study

2008 ◽  
Vol 15 (11) ◽  
pp. 1222-1230 ◽  
Author(s):  
H. Kasch ◽  
E. Qerama ◽  
A. Kongsted ◽  
T. Bendix ◽  
T. S. Jensen ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Prospective Study ◽  
Clinical Assessment ◽  
Whiplash Injury

CLINICAL ASSESSMENT FOR PROGNOSTIC FACTORS RELATED TO RECURRENCE AND PROGRESSION IN SUPERFICIAL BLADDER CANCER

1995 ◽  
Vol 86 (9) ◽  
pp. 1416-1423 ◽  
Author(s):  
Kazushiro Takei ◽  
Masaaki Hamano ◽  
Haruo Ito ◽  
Motoyuki Masai ◽  
Hirotoshi Minakami ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Prognostic Factors ◽  
Clinical Assessment ◽  
Superficial Bladder Cancer

Gene Mutations as Predicitive Markers for Postremission Therapy in Younger Adults with Normal Karyotype AML.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 4-4 ◽  
Author(s):  
Richard F. Schlenk ◽  
Andrea Corbacioglu ◽  
Jürgen Krauter ◽  
Lars Bullinger ◽  
Michael Morgan ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Induction Therapy ◽  
Gene Mutations ◽  
Normal Karyotype ◽  
Predictive Marker ◽  
Prognostic Impact ◽  
Npm1 Mutation ◽  
Genes Encoding ◽  
Postremission Therapy ◽  
Family Donor

Abstract Background: Mutations in the genes encoding NPM1, FLT3 (FLT3 ITD, FLT3 TKD), CEBPA, MLL (PTD) and NRAS have been identified as molecular markers in acute myeloid leukemia (AML) exhibiting a normal karyotype. Most recent studies focused on the prognostic value of single markers not taking into account their potential interactions. In addition, little is known about the predictive value of these markers on postremission therapy. Aims: To evaluate the prognostic impact of NPM1, FLT3, CEBPA, MLL and NRAS gene mutations on response to induction therapy, relapse-free (RFS) and overall survival (OS) as well as the predictive impact of these mutations on RFS and OS following different postremission therapies. Methods: Patients [16 to 60 years of age] were entered on four AMLSG treatment trials [AML-2/95, AML-1/99, AML HD93, AML HD98A]. As a consistent feature, in all four trials a genetic randomization was performed assigning all patients with an HLA-matched family donor (MRD) to allogeneic stem cell transplantation (SCT) in first complete remission (CR). Leukemia cells were analyzed for mutations in the above genes as previously described. Results: Between 1993 and 2004, 872 patients exhibiting a normal karyotype were registered. Median age was 48 years; median follow-up time was 49 months. Mutations were identified as follows (total number of samples analyzed; incidence of mutations): NPM1 (n=526; 53%), FLT3-ITD (n=531; 31%), FLT3-TKD (n=617; 11%), CEBPA (n=509; 14%), MLL-PTD (640; 8%), and NRAS (641; 13%). CR rate was 76%. In a logistic regression model, the NPM1+/FLT3-ITD- (p<.0001) and the CEBPA+ genotypes (p=0.05) were associated with induction success. Of 666 patients achieving a CR after induction therapy, 171 had a MRD and 143 (84%) of these received an allogeneic SCT in first CR. In survival analyses, the variable “availability of a MRD” was included on a strict intent-to-treat basis. Cox proportional hazard models for RFS and OS revealed age <48 years (hazard ratio (HR) 0.72 and 0.62, respectively), availability of a MRD (HR 0.62 and 0.75), the CEBPA+ (HR 0.42 and 0.36) and the NPM1+/FLT3-ITD- (HR 0.34 and 0.43) genotype as prognostic factors. To better define the role of allogeneic SCT in first CR, subgroup analyses were performed according to the combined FLT3-ITD and NPM1 mutation status (NPM1+/FLT3-ITD- versus all other combinations). These analyses revealed a marked difference in HR estimation for the variable “availability of a MRD”. In the NPM1+/FLT3-ITD- subgroup, HR for RFS and OS were 0.89 (95%-CI 0.49–1.64) and 0.93 (95%-CI 0.51–1.67) translating into a nearly equivalent RFS after 4 years of 61% (MRD) and 57% (no MRD). In contrast, in the subgroup defined by all other combinations of FLT3-ITD and NPM1 mutations, HR for RFS and OS were 0.56 (95%-CI 0.39–0.81) and 0.69 (95%-CI 0.48–0.98) translating into a marked difference in 4 years RFS of 47% (MRD) and 23% (no MRD). Conclusions: Specific genotypes emerge as highly significant prognostic factors for response to induction therapy and for survival in AML patients exhibiting a normal karyotype. The genotypic marker constellation NPM1+/FLT3-ITD- also fulfils the criteria of a predictive marker indicating a strong beneficial effect of allogeneic SCT in first CR only in the subgroup of patients without the NPM1+/FLT3-ITD- marker constellation.

The Clinical Assessment of Prognostic Factors in Bipolar Disorder- an Audit

2015 ◽  
Vol 30 ◽  
pp. 1120
Author(s):  
N. Verdolini ◽  
J. Dean ◽  
S. Elisei ◽  
R. Quartesan ◽  
R. Zaman ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Prognostic Factors ◽  
Clinical Assessment

scholarly journals The Vegetative State: A Review of Etiology and Prognostic Factors

2020 ◽  
Vol 7 (2) ◽  
Author(s):  
Rachel Elizabeth Davison
Keyword(s):  
Prognostic Factors ◽  
Diagnostic Criteria ◽  
Clinical Assessment ◽  
Clinical Condition ◽  
Vegetative State ◽  
Rare Syndrome ◽  
Patient Will

This paper reviews the research investigating the vegetative state (VS) in terms of its aetiology and prognostic factors that may be indicative of the outcome for patients in the VS. The VS is a relatively rare syndrome that still causes confusion for treating clinicians. In short, the VS is a clinical condition of unawareness of self and environment but with retained wakefulness. Until relatively recently there were no universally accepted diagnostic criteria, which caused problems both in terms of diagnosing the patient and in determining the incidence of the VS. This paper examines the most relevant and up to date work in order to determine if there is a way of predicting whether the VS for any given patient will be persistent (i.e. recovery is still possible) or if it is permanent and further treatment is futile. Currently, the most accurately available method to predict the prognosis of a patient in the VS is through clinical assessment of the patient combined with knowledge of the aetiology and duration of the VS. More work is needed in order to allow for the prediction of the outcome of the VS with greater certainty.

scholarly journals Foot symptom trajectories over seven years and relationship to potential prognostic factors: the clinical assessment study of the foot

2020 ◽  
Vol 28 ◽  
pp. S352
Author(s):  
M. Marshall ◽  
M. Blagojevic-Bucknall ◽  
T. Rathod-Mistry ◽  
M.J. Thomas ◽  
J. Edwards ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Clinical Assessment ◽  
Symptom Trajectories ◽  
Assessment Study

scholarly journals P154 Clinical assessment of prognosis and the prognostic factors in intestinal Bahcet’s disease

2018 ◽  
Vol 12 (supplement_1) ◽  
pp. S173-S174
Author(s):  
M Hachiya ◽  
T Sakurai ◽  
Y Nagata ◽  
A Hidaka ◽  
Y Akita ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Clinical Assessment

Prognostic value of BRAF and KRAS mutations in colorectal cancer patients.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14104-e14104
Author(s):  
Paola Murata ◽  
Agostina Stradella ◽  
David Páez ◽  
Maria Tobeña ◽  
Ana Sebio ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factors ◽  
Braf Mutation ◽  
Kras Mutation ◽  
Tumor Resection ◽  
Gene Mutations ◽  
Predictive Marker ◽  
Braf Mutations ◽  
Kras Mutations ◽  
Time To Relapse

e14104 Background: KRAS mutation has been established as a predictive marker of resistance to antiEGFR therapy in patients (pts) with colorectal cancer (CRC) but the role of BRAF is not yet clear. Both gene mutations have also been studied as prognostic factors but results are contradictory. AntiEGFR therapies impair evaluation of KRAS and BRAF as prognostic factors when overall survival is an endpoint. We hypothesized that if KRAS or BRAF were prognostic factors, they would influence time to relapse (TTR) after complete tumor resection. Methods: Patients who underwent surgery between 2007 and 2011 for stage II and III CRC were retrieved from our database. Codon 12 and 13 KRAS mutations and V600E BRAF mutation were analyzed. Clinical characteristics and mutation status were correlated with TTR. Results: We analyzed 170 pts with a median age of 66 (26 – 86) years. Tumors were located in the right colon in 27% of pts, in the transverse colon in 3%, in the left colon in 41%, and in the rectum in 29%. Most (55.3%) were stage III; 59% received adjuvant chemotherapy. KRAS and BRAF mutations were present in 66 (38.8%) and 5 (2.9%) pts respectively, and both were mutually exclusive. The most frequent KRAS mutations were: G12D (39.3%), G12V (27.2%), G13D (15.1%). Median TTR was 71 weeks (w) (95% CI 63-79). V600E BRAF mutation was the only factor associated with TTR. TTR was 42 w in tumors with the BRAF mutation and 74 w in wild-type tumors (p=0.041). Among KRAS mutations, KRAS G12V conferred a significantly longer TTR (100w) than the other subtype mutations (69 w; p=0.05). Conclusions: Our results suggest that V600E BRAF mutation is a negative prognostic factor in CRC, conferring a shorter time to relapse. Additionally, the KRAS G12V determines a different behavior among KRAS mutation tumors.

Sign in / Sign up

Export Citation Format

Share Document